We found that HCT116 cells with overexpressed MMP7 representative genes (TST and FUT3) were indeed more resistant to elesclomol treatment compared to control (Fig. 4g and Supplementary Fig. S18b), implying that patients with CRC with who have lower MMP7 scores may be more likely to benefit from elesclomol treatment. The gene discussed is TST; the disease is colorectal carcinoma.